Our analyses identified phosphorylated CDK2 to contribute to PAB-sensitivity of BC-PDMs, while other studies reported the opposite, as the cyclin E-CDK2 pathway is an important bypass mechanism of the cyclin D1-CDK4/6 axis in acquired PAB-resistance [134]. The gene discussed is CDK2; the disease is breast cancer.